PCIA
UBX

Prime Capital Investment Advisors’s Unity Biotechnology UBX Stock Holding History

Prime Capital Investment Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,420
Closed -$29.1K – 806
2023
Q2 		$29.1K Buy
+11,420
New +$30.2K ﹤0.01% 758
2023
Q1 		– Sell
-11,420
Closed -$31.3K – 655
2022
Q4 		$31.3K Buy
+11,420
New +$33.2K ﹤0.01% 518

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Prime Capital Investment Advisors's UBX Position: Q3 2023 in Review

Prime Capital Investment Advisors sold out of Unity Biotechnology (UBX) in Q3 2023, closing a stake of 11,420 shares — an estimated $29.1K sold.

Prime Capital Investment Advisors first reported a position in UBX in Q4 2022 and held it in 2 quarters. The position peaked at $31.3K in Q4 2022. 36 funds tracked by Wall St. Rank hold UBX as of Q3 2023.

  • Prime Capital Investment Advisors reported no remaining Unity Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 11,420 Unity Biotechnology shares in Q3 2023, an estimated $29.1K.
  • Prime Capital Investment Advisors first reported a position in Unity Biotechnology in Q4 2022 and held it in 2 quarters.
  • Prime Capital Investment Advisors's Unity Biotechnology position peaked at $31.3K in Q4 2022.
  • 36 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2023.

Based on Prime Capital Investment Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.